QUIDELORTHO CORP Gain (Loss) on Interest Rate Derivative Instruments Not Designated as Hedging Instruments
QUIDELORTHO CORP (QDEL) reported Gain (Loss) on Interest Rate Derivative Instruments Not Designated as Hedging Instruments of $0 for the 12-month period ending 2024-12-29, per its 10-K filed 2025-02-27.
Financial Statements › Income Statement › Other Income
us-gaap:GainLossOnInterestRateDerivativeInstrumentsNotDesignatedAsHedgingInstruments · last filed 2025-02-27
- QUIDELORTHO CORP gain (loss) on interest rate derivative instruments not designated as hedging instruments for fiscal 2024 was $0.00.
- QUIDELORTHO CORP gain (loss) on interest rate derivative instruments not designated as hedging instruments for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2023.
- QUIDELORTHO CORP gain (loss) on interest rate derivative instruments not designated as hedging instruments for fiscal 2023 was $3.40M.
- QUIDELORTHO CORP gain (loss) on interest rate derivative instruments not designated as hedging instruments for fiscal 2022 was $0.00.
| Period end | Gain (Loss) on Interest Rate Derivative Instruments Not Designated as Hedging Instruments 12 month |
|---|---|
| 2024-12-29 | $0.00 10-K · filed 2025-02-27 |
| 2023-12-31 | $0.00 10-K · filed 2025-02-27 |
| 2023-01-01 | $3.40M 10-K · filed 2025-02-27 |
| 2022-01-02 | $0.00 10-K/A · filed 2024-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |